Akebia Therapeutics Inc (AKBA)
1.845
+0.16
(+9.17%)
USD |
NASDAQ |
Nov 04, 16:00
1.85
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Net Income (Quarterly): -8.582M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -8.582M |
| March 31, 2024 | -17.98M |
| December 31, 2023 | 0.614M |
| September 30, 2023 | -14.49M |
| June 30, 2023 | -11.17M |
| March 31, 2023 | -26.88M |
| December 31, 2022 | -6.071M |
| September 30, 2022 | -54.10M |
| June 30, 2022 | 29.45M |
| March 31, 2022 | -62.42M |
| December 31, 2021 | -69.86M |
| September 30, 2021 | -59.54M |
| June 30, 2021 | -83.04M |
| March 31, 2021 | -69.58M |
| December 31, 2020 | -88.38M |
| September 30, 2020 | -59.96M |
| June 30, 2020 | -175.75M |
| March 31, 2020 | -60.75M |
| December 31, 2019 | -94.48M |
| September 30, 2019 | -54.58M |
| June 30, 2019 | -58.17M |
| March 31, 2019 | -72.42M |
| December 31, 2018 | -60.05M |
| Date | Value |
|---|---|
| September 30, 2018 | -26.05M |
| June 30, 2018 | -34.07M |
| March 31, 2018 | -23.42M |
| December 31, 2017 | 15.52M |
| September 30, 2017 | -23.13M |
| June 30, 2017 | -21.52M |
| March 31, 2017 | -44.54M |
| December 31, 2016 | -37.86M |
| September 30, 2016 | -36.31M |
| June 30, 2016 | -35.78M |
| March 31, 2016 | -25.80M |
| December 31, 2015 | -19.86M |
| September 30, 2015 | -19.48M |
| June 30, 2015 | -10.69M |
| March 31, 2015 | -10.70M |
| December 31, 2014 | -10.37M |
| September 30, 2014 | -9.348M |
| June 30, 2014 | -7.618M |
| March 31, 2014 | -9.697M |
| December 31, 2013 | -5.948M |
| September 30, 2013 | -3.768M |
| June 30, 2013 | -2.830M |
| March 31, 2013 | -0.6209M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-175.75M
Minimum
Jun 2020
29.45M
Maximum
Jun 2022
-49.10M
Average
-59.54M
Median
Sep 2021
Net Income (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 47.21M |
| Bioventus Inc | -23.99M |
| Eli Lilly and Co | 970.30M |
| NovaBay Pharmaceuticals Inc | -1.585M |
| Palatin Technologies Inc | -8.250M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 43.65M |
| Total Expenses (Quarterly) | 52.37M |
| EPS Diluted (Quarterly) | -0.04 |
| Enterprise Value | 386.51M |
| Gross Profit Margin (Quarterly) | 60.94% |
| Profit Margin (Quarterly) | -19.66% |
| Earnings Yield | -11.21% |
| Normalized Earnings Yield | -11.58 |